NCT00002855View on ClinicalTrials.gov

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

August 31, 1996

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Prostate Cancer
Interventions
DRUG

Bicalutamide

DRUG

Doxorubicin hydrochloride

DRUG

Estramustine Phosphate Sodium

DRUG

Flutamide

DRUG

Ketoconazole

DRUG

Nilutamide

DRUG

Therapeutic Hydrocortisone

DRUG

Vinblastine

PROCEDURE

Conventional Surgery

Surgical castration

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00002855 - Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer | Biotech Hunter | Biotech Hunter